The disclosure provides compositions and methods comprising selective inhibitors of Rho-associated coiled-coil kinase 2 (ROCK2) for use in the treatment of viral infections, particularly coro-navirus infections such as SARS-CoV-2, and in the treatment of seguelae resulting from the viral infection, including sequelae resulting from coronavirus infection.